Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

NCT05267535 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Piromelatine 20 mg
DRUG: Placebo

Sponsor

Neurim Pharmaceuticals Ltd.

Collaborators

[object Object]